Tel: +44 (0)1223 316 855
life science research products, biological research products, biotechnology
close ...


Supplier:
Product types:
Comprehensive Epigenetic Profiling and Screening Services
Ion Channel Screening & Profiling Services
Same Day Delivered Fresh Human Blood

Potassium, Voltage-Gated Channels

Cambridge Bioscience, through our collaboration with B’SYS, offers access to screening services for the following voltage-gated potassium channel targets:

Kv1.1
Gene Name: KCNA1
Description: The human KCNA1 gene encodes the pore-forming subunit of Kv1.1, a voltage-gated potassium channel. Mutations in KCNA1 cause several congenital disorders including episodic ataxia type 1, neuromyotonia and autosomal dominant hypomagnesia. Kv1.1 channels expressed in neurons are therapeutic targets in multiple sclerosis, stroke and seizure.

Kv1.2
Gene Name: KCNA2
Description: The human KCNA2 gene encodes the pore-forming subunit of Kv1.2, a voltage-gated potassium channel. Kv1.2 channels expressed in neurons are therapeutic targets in multiple sclerosis.

Kv1.3
Gene Name: KCNA3
Description: The human KCNA3 gene encodes the pore-forming subunit of Kv1.3, a voltage-gated potassium channel. Upregulation of Kv1.3 channels contributes to the activation of T-lymphocytes during inflammatory reactions; Kv1.3 channels are therapeutic targets in multiple sclerosis, cancer, obesity, diabetes, asthma and autoimmune diseases.

Kv1.4
Gene Name: KCNA4
Description: The human KCNA4 gene encodes the pore-forming subunit of Kv1.4, a voltage-gated potassium channel. Kv1.4 channels expressed in neurons are therapeutic targets for neuropathic pain treatment.

Kv1.5
Gene Name: KCNA5
Description: The human KCNA5 gene encodes the pore-forming subunit of Kv1.5, a voltage-gated potassium channel. A KCNA5 mutation has been linked to an inherited form of atrial fibrillation. Kv1.5 channels are widely expressed in heart, colon, kidney, vascular smooth muscle and the CNS and are therapeutic targets in atrial fibrillation, pulmonary hypertension, cancer and multiple sclerosis.

Kv1.6
Gene Name: KCNA6
Description: The human KCNA6 gene encodes the pore-forming subunit of a voltage-gated K+ channel. The hKv1.6 channel displays outward rectification, with fast activation and slow inactivation kinetics at depolarised potentials.

Kv2.1
Gene Name: KCNB1
Description: The human KCNB1 gene encodes a protein that forms a major part of delayed rectifier K+ current in the cortex and hippocampus. Modulation of Kv2.1 function has a large impact on the excitability of neurons. Kv2.1 is a therapeutic target in arrhythmia and has a role in action potential prolongation.

Kv4.3
Gene Name: KCND3
Description: The human KCND3 gene encodes the pore-forming subunit of Kv4.3, a voltage-gated potassium channel. Kv4.3 channels expressed in the heart are therapeutic targets in atrial fibrillation.

Kv4.3/KChIP
Gene Name: KCND3/KCNIP2
Description: The human KCND3 gene encodes the pore-forming subunit of Kv4.3, a voltage-gated potassium channel. KCNIP2 encodes an auxiliary subunit of the channel. Kv4.3/KChIP channels expressed in the heart are therapeutic targets in atrial fibrillation.

Kv7.1

Gene Name: KCNQ1
Description: Kv7.1 is a primary controller of the cardiac slow delayed rectifying current, which repolarises the cell to terminate the cardiac action potential. Kv7.1 is therefore of interest as a therapeutic target in aberrant QT syndromes and cardiac arrhythmia.

Kv7.1/minK
Gene Name: KCNQ1/MINK
Description: The human KCNQ1 gene encodes the pore-forming subunit of Kv7.1, a voltage-gated potassium channel. MinK modulates performance of the Kv7.1 channel, and the combined channel is a factor in several forms of long QT syndrome.

Kv7.2
Gene Name: KCNQ2
Description: The human KCNQ2 gene encodes one subunit of the M-channel, a slow activating/deactivating channel with a role in regulating neuronal excitability. This gene is linked with neonatal type-1 epilepsy, making it a target in the treatment of seizures and convulsions as well as migraines, dementia, bipolar disorder and neuropathic pain.

Kv7.3
Gene Name: KCNQ3
Description: The Kv7.3 channel is one of the major components of the M-current, a voltage dependent, non-inactivating potassium current that plays a role in integrating the activity of peripheral and central neurons. As with Kv7.2, Kv7.3 is a therapeutic target in the treatment of epilepsy, dementia, bipolar disorder and neuropathic pain.

Kv7.2/Kv7.3

Gene Name: KCNQ2/KCNQ3
Description: The human KCNQ2 and KCNQ3 genes encode the pore-forming subunits of Kv7.2 and Kv7.3, respectively. These subunits form heteromeric voltage-gated potassium channels that underlie the M-currents regulating repetitive neuronal activity. Mutations in KCNQ2 or KCNQ3 that reduce M-current amplitude are responsible for some forms of benign familial neonatal seizure. Kv7.2/Kv7.3 channels are therapeutic targets in seizure, stroke, migraine, dementia, bipolar disorder, anxiety and neuropathic pain.

Kv11.1 (hERG)
Gene Name: KCNH2
Description: The human KCNH2 gene encodes the pore-forming subunit of Kv11.1, the voltage-gated hERG potassium channel. hERG channels are upregulated in some types of cancer and may serve as a tumor marker. KCNH2 mutations cause inherited forms of cardiac disorders including both long QT (loss-of-function) and short QT (gain-of-function) syndromes. Inhibition of hERG channels by pharmaceuticals is the primary cause of acquired long QT syndrome and drug-induced Torsade de Pointes. Therefore, hERG is an anti-target in cardiac risk assessment.

Speak to a Specialist
To discuss a voltage gated potassium channel screening project with one of our specialists, please Click Here

Contact Our B'SYS Specialist, Vashu